Af­ter blue­print­ing R&D hub, Ab­b­Vie dish­es out $105M for CD39 pact with Tizon­a's new CEO from Roche

With the $10 bil­lion Ro­va-T pro­gram seem­ing­ly head­ed to­ward the cliff, Ab­b­Vie is turn­ing to an ear­ly-stage col­lab­o­ra­tion for a longer shot at can­cer drug suc­cess.

For its lat­est for­ay in­to the tu­mor mi­croen­vi­ron­ment, Ab­b­Vie has part­nered up Tizona Ther­a­peu­tics, an MPM-found­ed biotech lo­cat­ed just up the road from the on­col­o­gy R&D hub that Ab­b­Vie is build­ing at Oys­ter Point, South San Fran­cis­co.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.